Showing 2491-2500 of 5771 results for "".
- RevolutionEHR Announces Early Access to Redesigned Patient Portalhttps://modernod.com/news/revolutionehr-announces-early-access-to-redesigned-patient-portal/2485693/RevolutionEHR, a cloud-based electronic health record and practice management platform for optometry,
- American Academy of Optometry Announces 2025 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2025-award-recipients/2484131/Each year, the American Academy of Optometry (AAOpt) recognizes distinguished individuals whose contributions advance the profession of optometry and vision science. The Academy’s awardees are nominated by fellows and are based on contributions made in t
- Sydnexis Announces European Commission Approval of Ryjunea, the First Treatment for Slowing the Progression of Pediatric Myopiahttps://modernod.com/news/sydnexis-announces-european-commission-approval-of-ryjunea-first-treatment-for-slowing-the-progression-of-pediatric-myopia/2482839/The European Commission (EC) has granted marketing authorization for Sydnexis' SYD-101 (branded as Ryjunea), the company’s proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia.
- Prevent Blindness Announces Matt MacDonald as Chair-Elect of Board of Directorshttps://modernod.com/news/prevent-blindness-announces-matt-macdonald-as-chair-elect-of-board-of-directors/2482708/Prevent Blindness, a nonprofit organization dedicated to eye health and safety awareness, named Matt MacDonald as Chair-elect of its Board of Directors. The vote was held last week during the Spring 2025 Board Meeting. He will succeed current Board of Directors Chair Jim McGrann, CEO of Adva
- Alcon Announces US Launch of Systane PRO PF for Dry Eye Reliefhttps://modernod.com/news/alcon-announces-us-launch-of-systane-pro-pf-for-dry-eye-relief/2482678/Alcon has launched Systane PRO Preservative-Free (PF) in the US, the latest addition to its over-the-counter dry eye portfolio. According to Alcon, Systane PRO PF is the longest-lasting eye drop in the Systane lineup, offering a tr
- Inflammasome Therapeutics Announces Positive Topline Data from K8 Implant Trial for GAhttps://modernod.com/news/inflammasome-therapeutics-announces-positive-topline-data-from-k8-implant-trial-for-geographic-atrophy/2482621/Inflammasome Therapeutics reported 3-month results from a clinical trial of its K8 implant in patients with geographic atrophy (GA). The study, conducted at the University of Kentucky (NCT06164587), demonstrated significant efficacy and safety following a single inject
- Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Study of Brimochol PF for Presbyopiahttps://modernod.com/news/tenpoint-therapeutics-announces-positive-topline-data-from-phase-3-pivotal-study-of-brimochol-pf-for-the-treatment-of-presbyopia/2482609/Tenpoint Therapeutics reported positive topline results from BRIO-II, the company’s second phase 3 pivotal trial. BRIO-II met the prespecified primary endpoints agreed upon with the FDA, and European Medicines Agency (EMA), and the UK Medicines and Healthcare products Regulatory Agency
- Adverum Announces Postive LUNA Phase 2 and OPTIC Long-Term Data on Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-announces-postive-luna-phase-2-and-optic-long-term-data-on-gene-therapy-for-wet-amd/2482546/Adverum Biotechnologies has released 52-week topline results from its phase 2 LUNA trial and new 4-year follow-up data from the OPTIC phase 1/2 study on its wet AMD gene therapy candidate Ixo-vec (AAV.7m8-aflibercept). “We are thrilled to report 52-week LUNA d
- Corxel and Lenz Therapeutics Announce Positive Phase 3 Trial Results for Presbyopia Eye Drop LNZ100 in Chinahttps://modernod.com/news/corxel-pharmaceuticals-and-lenz-therapeutics-announce-positive-phase-3-trial-results-for-presbyopia-eye-drop-lnz100-in-china/2482519/Lenz Therapeutics and its parner Corxel Pharmaceuticals unveiled phase 3 trial results from the China-based JX07001 study, showing that LNZ100, an aceclidine-based eye drop, achieved significant improvement in near vision for presbyopia patients. The study's topline results demonstr
- EyePoint Pharma Announces Positive Interim Results for Duravyu in Phase 2 VERONA Trial for DMEhttps://modernod.com/news/eyepoint-pharma-announces-positive-interim-results-for-duravyu-in-phase-2-verona-trial-for-dme/2482516/EyePoint Pharmaceuticals reported interim 16-week data from its ongoing phase 2 VERONA clinical trial, which is assessing the investigational sustained delivery therapy Duravyu. The therapy, developed for patients with diabetic macular edema (DME), leverages a proprietary bioerodible Duraser